Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1966 4
1967 6
1968 3
1969 7
1970 11
1971 6
1972 8
1973 4
1974 6
1975 6
1976 12
1977 6
1978 3
1979 18
1980 14
1981 11
1982 8
1983 5
1984 11
1985 9
1986 19
1987 12
1988 18
1989 10
1990 18
1991 21
1992 21
1993 25
1994 32
1995 41
1996 50
1997 35
1998 30
1999 36
2000 25
2001 35
2002 29
2003 41
2004 41
2005 44
2006 35
2007 45
2008 26
2009 32
2010 35
2011 25
2012 34
2013 35
2014 15
2015 26
2016 18
2017 19
2018 15
2019 23
2020 18
2021 21
2022 14
2023 11
2024 11
2025 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,137 results

Results by year

Filters applied: . Clear all
Page 1
Comparative Effectiveness of Levothyroxine, Desiccated Thyroid Extract, and Levothyroxine+Liothyronine in Hypothyroidism.
Shakir MKM, Brooks DI, McAninch EA, Fonseca TL, Mai VQ, Bianco AC, Hoang TD. Shakir MKM, et al. J Clin Endocrinol Metab. 2021 Oct 21;106(11):e4400-e4413. doi: 10.1210/clinem/dgab478. J Clin Endocrinol Metab. 2021. PMID: 34185829 Free PMC article. Clinical Trial.
INTRODUCTION: Studies comparing levothyroxine (LT4) therapy with LT4 + liothyronine (LT3) or desiccated thyroid extract (DTE) did not detect consistent superiority of either treatment. ...
INTRODUCTION: Studies comparing levothyroxine (LT4) therapy with LT4 + liothyronine (LT3) or desiccated thyroid extract (DTE) …
A feasibility double-blind trial of levothyroxine vs. levothyroxine-liothyronine in postsurgical hypothyroidism.
Phan GQ, Yavuz S, Stamatouli AM, Madan R, Chen S, Grover AC, Nilubol N, Bedoya P, Trankle C, Markley R, Abbate A, Celi FS. Phan GQ, et al. Front Endocrinol (Lausanne). 2025 Mar 10;16:1522753. doi: 10.3389/fendo.2025.1522753. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 40130156 Free PMC article. Clinical Trial.
CONTEXT: Despite normalization of Thyrotropin (TSH), some patients with hypothyroidism treated with Levothyroxine (LT4) report residual symptoms which may be attributable to loss of endogenous triiodothyronine (T3). OBJECTIVE: Feasibility trial LT4/liothyronine …
CONTEXT: Despite normalization of Thyrotropin (TSH), some patients with hypothyroidism treated with Levothyroxine (LT4) report residu …
Randomized double-blind placebo-controlled trial on levothyroxine and liothyronine combination therapy in totally thyroidectomized subjects: the LEVOLIO study.
Brigante G, Santi D, Boselli G, Margiotta G, Corleto R, Monzani ML, Craparo A, Locaso M, Sperduti S, Roy N, Casarini L, Trenti T, Tagliavini S, De Santis MC, Roli L, Rochira V, Simoni M. Brigante G, et al. Eur J Endocrinol. 2024 Jan 3;190(1):12-22. doi: 10.1093/ejendo/lvad172. Eur J Endocrinol. 2024. PMID: 38124252 Clinical Trial.
The primary aim of this study was to evaluate the effect of twice-daily, combination therapy with levothyroxine (LT4) and liothyronine (LT3), at doses adapted according to TSH-level, on peripheral tissues as reflected by sex hormone binding globulin (SHBG) levels in …
The primary aim of this study was to evaluate the effect of twice-daily, combination therapy with levothyroxine (LT4) and liothyro …
Pharmacodynamic and pharmacokinetic properties of the combined preparation of levothyroxine plus sustained- release liothyronine; a randomized controlled clinical trial.
Mehran L, Amouzegar A, Foroutan SM, Masoumi S, Tohidi M, Abdi H, Aghaei A, Saghafinia AE, Azizi F. Mehran L, et al. BMC Endocr Disord. 2023 Aug 28;23(1):182. doi: 10.1186/s12902-023-01434-y. BMC Endocr Disord. 2023. PMID: 37641049 Free PMC article. Clinical Trial.
BACKGROUND: Understanding pharmacokinetics (PK) and pharmacodynamics (PD) of the sustained-release liothyronine (SR-T3) is of paramount importance to design therapeutic regimens that are able to simulate normal thyroid hormone secretion while avoiding excursions in the T3 …
BACKGROUND: Understanding pharmacokinetics (PK) and pharmacodynamics (PD) of the sustained-release liothyronine (SR-T3) is of paramou …
Preliminary Results of a Double-Blind Randomized Controlled Trial Evaluating the Cardiometabolic Effects of Levothyroxine and Liothyronine Compared to Levothyroxine with Placebo in Athyreotic Low-Risk Thyroid Cancer Patients.
Biondi B, Pucci M, Pontieri G, Formisano P, Esposito R. Biondi B, et al. Thyroid. 2023 Dec;33(12):1402-1413. doi: 10.1089/thy.2023.0135. Epub 2023 Oct 23. Thyroid. 2023. PMID: 37725587 Clinical Trial.
Background: Evidence is needed on the risks and benefits of combination therapy with levothyroxine (LT4)+liothyronine (LT3) for the treatment of hypothyroidism. Objective and Methods: We performed a randomized, double-blind placebo-controlled study to assess the eff …
Background: Evidence is needed on the risks and benefits of combination therapy with levothyroxine (LT4)+liothyronine (LT3) fo …
Hypothyroidism.
Cohlmia JB, Whittier FC, Meek JC, Grantham JJ. Cohlmia JB, et al. Proc Clin Dial Transplant Forum. 1975 Nov;5:136-8. Proc Clin Dial Transplant Forum. 1975. PMID: 785453 Clinical Trial.
Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial.
Clyde PW, Harari AE, Getka EJ, Shakir KM. Clyde PW, et al. JAMA. 2003 Dec 10;290(22):2952-8. doi: 10.1001/jama.290.22.2952. JAMA. 2003. PMID: 14665656 Clinical Trial.
CONTEXT: Standard therapy for patients with primary hypothyroidism is replacement with synthetic thyroxine, which undergoes peripheral conversion to triiodothyronine, the active form of thyroid hormone. Within the lay population and in some medical communities, ther …
CONTEXT: Standard therapy for patients with primary hypothyroidism is replacement with synthetic thyroxine, which undergoes periphera …
Efficacy of combined levothyroxine and liothyronine as compared with levothyroxine monotherapy in primary hypothyroidism: a randomized controlled trial.
Valizadeh M, Seyyed-Majidi MR, Hajibeigloo H, Momtazi S, Musavinasab N, Hayatbakhsh MR. Valizadeh M, et al. Endocr Res. 2009;34(3):80-9. doi: 10.1080/07435800903156340. Endocr Res. 2009. PMID: 19701833 Clinical Trial.
OBJECTIVES: To examine the efficacy of combination therapy with levothyroxine and liothyronine in improvement of general health, psychological problems, and metabolic status in primary hypothyroidism. METHODS: Seventy-one patients diagnosed with primary hypothyroidi …
OBJECTIVES: To examine the efficacy of combination therapy with levothyroxine and liothyronine in improvement of general healt …
Combined therapy with levothyroxine and liothyronine in two ratios, compared with levothyroxine monotherapy in primary hypothyroidism: a double-blind, randomized, controlled clinical trial.
Appelhof BC, Fliers E, Wekking EM, Schene AH, Huyser J, Tijssen JG, Endert E, van Weert HC, Wiersinga WM. Appelhof BC, et al. J Clin Endocrinol Metab. 2005 May;90(5):2666-74. doi: 10.1210/jc.2004-2111. Epub 2005 Feb 10. J Clin Endocrinol Metab. 2005. PMID: 15705921 Clinical Trial.
Controversy remains about the value of combined treatment with levothyroxine (LT4) and liothyronine (LT3), compared with LT4 alone in primary hypothyroidism. ...
Controversy remains about the value of combined treatment with levothyroxine (LT4) and liothyronine (LT3), compared with LT4 a …
Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial.
Cooper-Kazaz R, Apter JT, Cohen R, Karagichev L, Muhammed-Moussa S, Grupper D, Drori T, Newman ME, Sackeim HA, Glaser B, Lerer B. Cooper-Kazaz R, et al. Arch Gen Psychiatry. 2007 Jun;64(6):679-88. doi: 10.1001/archpsyc.64.6.679. Arch Gen Psychiatry. 2007. PMID: 17548749 Clinical Trial.
BACKGROUND: Antidepressant treatments that achieve a higher remission rate than those currently available are urgently needed. The thyroid hormone triiodothyronine may potentiate antidepressant effects. OBJECTIVE: To determine the antidepressant efficacy and safety of l …
BACKGROUND: Antidepressant treatments that achieve a higher remission rate than those currently available are urgently needed. The thyroid h …
1,137 results